Lukaczer D, Darland G, Tripp M, et al. A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia. Phytother Res. Oct 2005;19(10):864-869.
An eight-week observational trial of a proprietary blend (Meta050) of hops extract, rosemary extract, and oleanolic acid was conducted in patients suffering from osteoarthritis, rheumatoid arthritis and fibromyalgia. A dose of 440 mg of the product Meta050 was given three times a day for the first 4 weeks and then changed to 880mg twice per day in most patients for the concluding 4 weeks. Fifty-four patients completed the trial. There was a statistically significant reduction in pain post-treatment for the OA patients. Pain scores decreased 50% (P<0.0001) as measured by standard visual analog (VAS), and 40% (P<0.0001) as measured by the arthritis impact measurement scale (AIMS2). There was no significant improvement in fibromyalgia scores. In patients who initially presented with elevated high-sensitivity C-reactive protein, a decreasing trend was observed. The authors note that these observations suggest that 440mg three times per day of Meta050 may provide pain-relieving effects in osteoarthritis patients. Financial support for the study was provided by the manufacturer of Meta050.
Heyerick A, Vervarcke S, Depypere H, Bracke M, et al. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas. May 20 2006;54(2):164-175.
Sixty-seven women with menopausal symptoms participated in a 12-week prospective, randomized, double-blind, placebo-controlled trial using supplemental hops extract standardized to 100 or 250mcg 8-prenylnaringen (8-PN). Patient responses were assessed by means of a modified Kupperman Index (KI) and a patient questionnaire. The daily dose of 100ug 8-PN significantly reduced discomfort and complaints compared to placebo at 6 weeks (P=0.023), but not at 12 weeks (P=0.086). A statistically significant decrease in the incidence of hot flushes was evident in both treatment groups after 6 weeks compared to placebo. A dose-response relationship could not be established as a 2.5 fold increase in dose was less active than the lower dose after 6 and 12 weeks, and the 250mcg dose was only marginally more effective than placebo. The authors suggest that hops extracts may be beneficial for hot flash management. The study was designed and funded by the manufacturers of the proprietary supplement MenoHop used in the study.